Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.

Bibliographic Details
Title: Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.
Authors: Vargas, Mario H., Chávez, Jaime, Del-Razo-Rodríguez, Rosangela, Muñoz-Perea, Carolina, Romo-Domínguez, Karina Julieta, Báez-Saldaña, Renata, Rumbo-Nava, Uriel, Guerrero-Zúñiga, Selene
Source: Scientific Reports; 5/21/2024, Vol. 11 Issue 1, p1-10, 10p
Subject Terms: CLINICAL trials, GLYCINE, COVID-19, TREATMENT effectiveness, ARTIFICIAL respiration, CYTOPROTECTION
Abstract: There is a worrying scarcity of drug options for patients with severe COVID-19. Glycine possesses anti-inflammatory, cytoprotective, endothelium-protective, and platelet-antiaggregant properties, so its use in these patients seems promising. In this open label, controlled clinical trial, inpatients with severe COVID-19 requiring mechanical ventilation randomly received usual care (control group) or usual care plus 0.5 g/kg/day glycine by the enteral route (experimental group). Major outcomes included mortality, time to weaning from mechanical ventilation, total time on mechanical ventilation, and time from study recruitment to death. Secondary outcomes included laboratory tests and serum cytokines. Patients from experimental (n = 33) and control groups (n = 23) did not differ in basal characteristics. There were no differences in mortality (glycine group, 63.6% vs control group, 52.2%, p = 0.60) nor in any other major outcome. Glycine intake was associated with lower fibrinogen levels, either evaluated per week of follow-up (p < 0.05 at weeks 1, 2, and 4) or as weighted mean during the whole hospitalization (608.7 ± 17.7 mg/dl vs control 712.2 ± 25.0 mg/dl, p = 0.001), but did not modify any other laboratory test or cytokine concentration. In summary, in severe COVID-19 glycine was unable to modify major clinical outcomes, serum cytokines or most laboratory tests, but was associated with lower serum fibrinogen concentration. Registration: ClinicalTrials.gov NCT04443673, 23/06/2020. [ABSTRACT FROM AUTHOR]
Copyright of Scientific Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
More Details
ISSN:20452322
DOI:10.1038/s41598-024-62321-7
Published in:Scientific Reports
Language:English